Brokerages Set AnaptysBio, Inc. (NASDAQ:ANAB) Price Target at $46.22

Shares of AnaptysBio, Inc. (NASDAQ:ANAB) have earned an average recommendation of “Moderate Buy” from the ten research firms that are covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $46.22.

A number of research firms have issued reports on ANAB. SVB Leerink started coverage on AnaptysBio in a research note on Tuesday, April 16th. They issued an “outperform” rating and a $47.00 price objective on the stock. Stifel Nicolaus began coverage on shares of AnaptysBio in a research note on Wednesday, February 21st. They set a “buy” rating and a $50.00 price target on the stock. Leerink Partnrs reiterated an “outperform” rating on shares of AnaptysBio in a research report on Tuesday, April 16th. Piper Sandler assumed coverage on shares of AnaptysBio in a report on Friday, February 16th. They issued an “overweight” rating and a $80.00 target price on the stock. Finally, Wells Fargo & Company started coverage on shares of AnaptysBio in a report on Thursday, April 11th. They issued an “overweight” rating and a $56.00 price target for the company.

AnaptysBio Stock Performance

Shares of NASDAQ ANAB opened at $26.58 on Wednesday. The company has a market cap of $726.17 million, a P/E ratio of -4.37 and a beta of -0.32. AnaptysBio has a 52-week low of $13.36 and a 52-week high of $27.50. The firm’s fifty day moving average is $22.93 and its two-hundred day moving average is $20.81.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Monday, March 11th. The biotechnology company reported ($1.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.74) by $0.15. The firm had revenue of $9.01 million for the quarter, compared to analysts’ expectations of $3.28 million. AnaptysBio had a negative return on equity of 119.42% and a negative net margin of 953.66%. As a group, analysts forecast that AnaptysBio will post -6.17 EPS for the current fiscal year.

Insider Transactions at AnaptysBio

In other AnaptysBio news, CEO Daniel Faga sold 3,000 shares of the firm’s stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $21.42, for a total value of $64,260.00. Following the completion of the sale, the chief executive officer now owns 749,087 shares of the company’s stock, valued at $16,045,443.54. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, insider Eric J. Loumeau sold 5,000 shares of the business’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $25.00, for a total transaction of $125,000.00. Following the completion of the sale, the insider now directly owns 3,240 shares of the company’s stock, valued at $81,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Daniel Faga sold 3,000 shares of the firm’s stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $21.42, for a total transaction of $64,260.00. Following the completion of the transaction, the chief executive officer now directly owns 749,087 shares in the company, valued at approximately $16,045,443.54. The disclosure for this sale can be found here. In the last quarter, insiders sold 153,940 shares of company stock worth $3,513,773. 35.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On AnaptysBio

Hedge funds have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of AnaptysBio during the first quarter valued at approximately $265,000. Allspring Global Investments Holdings LLC bought a new stake in AnaptysBio during the 1st quarter valued at $38,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of AnaptysBio by 66.8% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 5,123 shares of the biotechnology company’s stock worth $115,000 after buying an additional 2,051 shares during the period. Fisher Asset Management LLC grew its position in shares of AnaptysBio by 0.7% during the 4th quarter. Fisher Asset Management LLC now owns 71,154 shares of the biotechnology company’s stock worth $1,524,000 after buying an additional 500 shares in the last quarter. Finally, Octagon Capital Advisors LP purchased a new position in shares of AnaptysBio during the fourth quarter valued at $2,570,000.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.